

cobas[®] Zika**Nucleic acid test
for use on the cobas**[®] **6800/8800 Systems***For in vitro diagnostic use*

| | |
|--|------------------|
| cobas [®] Zika – 480 | P/N: 07972466190 |
| cobas [®] Zika Control Kit | P/N: 08129690190 |
| cobas [®] NHP Negative Control Kit | P/N: 07002220190 |
| cobas omni MGP Reagent | P/N: 06997546190 |
| cobas omni Specimen Diluent | P/N: 06997511190 |
| cobas omni Lysis Reagent | P/N: 06997538190 |
| cobas omni Wash Reagent | P/N: 06997503190 |

Table of contents

| | |
|--|-----------|
| Intended use | 4 |
| Summary and explanation of the test | 4 |
| Reagents and materials | 7 |
| cobas® Zika reagents and controls | 7 |
| cobas omni reagents for sample preparation | 9 |
| Reagent storage and handling requirements | 11 |
| Additional materials required | 12 |
| Instrumentation and software required | 12 |
| Precautions and handling requirements | 12 |
| Warnings and precautions | 13 |
| Reagent handling | 13 |
| Good laboratory practice | 14 |
| Sample collection, transport and storage | 14 |
| Living donor samples | 14 |
| Instructions for use | 17 |
| Automated sample pipetting and pooling (optional) | 17 |
| Procedural notes | 17 |
| Running cobas® Zika | 17 |
| Results | 18 |
| Quality control and validity of results | 18 |
| Interpretation of results | 18 |
| Procedural limitations | 19 |
| Non-clinical performance evaluation | 20 |
| Key performance characteristics - Living donor samples | 20 |
| Limit of Detection (LoD) | 20 |
| Analytical specificity | 21 |
| Detection of Zika virus at LoD in clinical samples | 22 |

Clinical performance evaluation 23

- Reproducibility..... 23
- Clinical specificity..... 24
- Evaluation of the sensitivity of **cobas® Zika**..... 24
- Evaluation of the yield and PPV of **cobas® Zika** in a Zika outbreak..... 24
- Evaluation of pool reactivity of **cobas® Zika** 25

Additional information..... 26

- Key test features 26
- Symbols..... 27
- Manufacturer and distributors 29
- Trademarks and patents..... 29
- Copyright..... 29
- References..... 30
- Document revision 32

Intended use

The **cobas**® Zika test for use on the **cobas**® 6800 and **cobas**® 8800 Systems is a qualitative *in vitro* nucleic acid screening test for the direct detection of Zika virus RNA in human plasma.

This test is intended for use to screen donor samples for Zika virus RNA in plasma samples from individual human donors, including donors of whole blood and blood components, and other living donors. This test is also intended for use to screen organ and tissue donors when donor samples are obtained while the donor's heart is still beating.

Plasma from all donors may be screened as individual samples. For donations of whole blood and blood components, plasma samples may be tested individually or in pools comprised of not more than six individual samples.

The test is not intended for use as an aid in diagnosis of Zika virus infection.

This test is not intended for use on samples of other body fluids.

This test is not intended for use on samples of cord blood.

Summary and explanation of the test

Background

Zika virus is an enveloped, icosahedral, single-stranded RNA arbovirus of the family Flaviviridae, genus Flavivirus. The Flaviviridae family includes West Nile virus (WNV), dengue virus, yellow fever virus, and about 70 other viruses.¹⁻⁴ Zika appears to be closely related to the Spondweni virus, which has been identified in South Africa.^{1,5}

Zika virus was first isolated in 1947 from a Rhesus monkey in the Zika forest of Uganda and subsequently identified in an *Aedes africanus* mosquito captured in that forest.¹ The first three human cases were reported during a jaundice epidemic in Eastern Nigeria in 1954.¹ Zika virus has been identified in multiple countries in Africa, Asia, the Pacific Ocean, and South America.¹ A large outbreak in Brazil started in May 2015, with estimated 440,000-1,300,000 cases identified by the end of 2015.⁶ By early January 2016, autochthonous Zika virus cases had been reported in more than 20 countries and territories in the Caribbean (including Puerto Rico and the U.S. Virgin Islands), Central America, and South America.⁶

Zika virus is transmitted to humans by *Aedes* mosquito species.¹ *Aedes albopictus* was described as a potential vector of Zika in 2007.^{5,6,7,10,11} Zika virus may be transmitted via transfusion.^{1,9,11,12-15} Zika has been detected in semen¹⁶ and reported to have been transmitted through sexual intercourse.¹⁶⁻²⁰ Zika may also be transmitted from a pregnant woman to her fetus,²¹⁻²³ from a mother to her newborn at birth,^{1,23} and through laboratory exposure.⁶ Neither transmission through organ nor tissue transplantation has been documented but is theoretically possible.⁶ Zika virus RNA has been detected in breast milk, but transmission through breastfeeding has not been documented.^{6,23}

Limited data exist about the prevalence of Zika virus in blood donors.¹ Molecular analyses performed during the outbreak in French Polynesia in 2013 are the principal source of data.^{1,11} The risk of asymptomatic persons donating blood raises concern for transfusion-related transmission and was demonstrated in the French Polynesian outbreak. There, 42 of 1,505 (2.8%) asymptomatic blood donors were positive by reverse transcription polymerase chain reaction (RT-PCR) for Zika.^{1,11} Only 11 of the 42 persons infected with Zika reported a "Zika fever-like syndrome" 3 to 10 days after they donated blood.^{1,18}

Zika is asymptomatic in most (estimated 80%) cases.^{1,6,9,17} When symptomatic, Zika virus usually presents with non-specific, influenza-like signs and symptoms, such as mild fever, arthralgia (small joints of hands and feet), myalgia, headache, retro-orbital pain, conjunctivitis, abdominal pain, and a maculopapular, frequently pruritic, rash; edema and

lymphadenopathy may also be present.^{1,5} A causal link between Zika and the occurrence of other severe neurologic symptoms, including Guillain-Barré syndrome, is still under investigation.^{5,15,23} Zika infection at any time during pregnancy appears to be associated with adverse pregnancy outcomes, including congenital malformations, intrauterine growth restriction, and fetal death.²⁴

The symptoms typically appear a few days after the bite of an infected mosquito and usually last 3 to 12 days.^{5,14} Treatment is usually supportive, including rest, fluids, acetaminophen, and antihistamines.⁵ Zika is difficult to distinguish clinically from other arboviruses, including dengue fever, chikungunya, and WNV.¹

Serological tests (enzyme-linked immunosorbent assay [ELISA] or immunofluorescence) for Zika virus have been developed.¹ Cross-reactivity with other flaviviruses, including dengue or yellow fever, limits the utility of an IgM antibody diagnostic test.¹ In addition, antibodies may not be present in the early phase of the infection, which further reduces the suitability of a serologic test for acute infection.⁵ Diagnosis of acute Zika virus infection is primarily based on detection of viral RNA from specimens via RT-PCR. The viremic period has not been established, but it is believed to be short, with direct virus detection during the first 3 to 5 days after the onset of symptoms.^{1,8,25} In one study, the viral RNA concentrations were between approximately 900 and 729,000 copies/mL.⁸ Viremia as high as 8.1×10^6 has been reported.¹⁴ Most of the Zika-positive samples were from specimens collected three days or less after symptom onset, although one specimen collected on day 11 after onset had an estimated titer of 339,000 copies/mL.⁸ No vaccine for Zika currently exists.⁵

Rationale for NAT testing

Zika virus can be transmitted via transfusion.^{1,9,11,12-15} Most (about 80%) Zika infections are asymptomatic, so infected individuals may donate blood.^{1,6,9,17} Because infected donors may not develop clinically-significant disease or remain asymptomatic, questioning blood donors about recent symptoms suggestive of Zika infection is ineffective at identifying infected donors.

Like other infectious diseases for which blood donations are screened, blood donations must be screened with a sensitive assay to detect Zika RNA so that infected units may be interdicted and discarded. The **cobas**® Zika test will offer novel capability to detect Zika RNA and thereby provide heightened protection from transfusion-transmitted Zika infection for recipients of donated blood components or products and will further improve the safety of the blood supply.

Explanation of the test

cobas® Zika is a qualitative test that is run on the **cobas**® 6800 System and **cobas**® 8800 System. **cobas**® Zika enables the simultaneous detection of Zika virus RNA and the internal control in a single test of an infected, individual donation or pooled plasma from individual donations .

Principles of the procedure

cobas® Zika is based on fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection. The **cobas**® 6800/8800 Systems consist of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the **cobas**® 6800/8800 software which assigns test results for all tests as non-reactive, reactive, or invalid. Results can be reviewed directly on the system screen, and printed as a report.

Samples should be tested as individual samples or, optionally, can be tested in pools consisting of multiple samples. The **cobas**® Synergy software with the Hamilton MICROLAB® STAR IVD (**cobas**® Synergy Core), may optionally be used in a pre-analytical step if pooling is to be performed.

Nucleic acids from the sample and added armored RNA internal control (IC) molecules (which serve as the sample preparation and amplification/detection process control) are simultaneously extracted. In addition the test utilizes two external controls: a positive and a negative control. Viral nucleic acids are released by addition of proteinase and lysis reagent to the sample. The released nucleic acids bind to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured proteins, cellular debris, and potential PCR inhibitors (such as hemoglobin) are removed with subsequent wash reagent steps and purified nucleic acids are eluted from the glass particles with elution buffer at elevated temperature.

Selective amplification of target nucleic acid from the donor sample is achieved by the use of virus-specific forward and reverse primers which are selected from highly conserved regions of the viral nucleic acid. A thermostable DNA polymerase enzyme is used for both reverse-transcription and amplification. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythymidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon).²⁶⁻²⁸ Any contaminating amplicons from previous PCR runs are destroyed by the AmpErase enzyme [uracil-N-glycosylase], which is included in the PCR mix, when heated in the first thermal cycling step. However, newly formed amplicons are not destroyed since the AmpErase enzyme is inactivated once exposed to temperatures above 55°C.

The **cobas**® Zika master mix contains detection probes which are specific for Zika virus and IC nucleic acid. The specific Zika virus and IC detection probes are each labeled with one of two unique fluorescent dyes which acts as a reporter. Each probe also has a second dye which acts as a quencher. The two reporter dyes are measured at defined wavelengths, thus permitting detection and discrimination of the amplified Zika virus target and the IC.^{29, 30} When not bound to the target sequence, the fluorescent signal of the intact probes is suppressed by the quencher dye. During the PCR amplification step, hybridization of the probes to the specific single-stranded DNA template results in cleavage by the 5' to 3' nuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye is concomitantly increased. Since the two specific reporter dyes are measured at defined wavelengths, simultaneous detection and discrimination of the amplified Zika target and the IC are possible.

Reagents and materials

cobas® Zika reagents and controls

All unopened reagents and controls shall be stored as recommended in [Table 1](#) to [Table 4](#).

Table 1 cobas® Zika

Store at 2-8°C


480 test cassette (P/N 07972466190)

| Kit components | Reagent ingredients | Quantity per kit 480 tests |
|--|--|-------------------------------|
| Proteinase Solution (PASE) | Tris buffer, < 0.05% EDTA, calcium chloride, calcium acetate, 8% (w/v) proteinase EUH210: Safety data sheet available on request. EUH208: Contains subtilisin. May produce an allergic reaction. | 38 mL |
| Internal Control (IC) | Tris buffer, < 0.05% EDTA, < 0.001% internal control armored RNA construct (non-infectious RNA encapsulated in MS2 bacteriophage), < 0.002% Poly rA RNA (synthetic), < 0.1% sodium azide | 38 mL |
| Elution Buffer (EB) | Tris buffer, 0.2% methyl-4 hydroxybenzoate | 38 mL |
| Master Mix Reagent 1 (MMX-R1) | Manganese acetate, potassium hydroxide, < 0.1% sodium azide | 14.5 mL |
| Zika Master Mix Reagent 2 (ZIKA MMX-R2) | Tricine buffer, potassium acetate, glycerol, 18% dimethyl sulfoxide, < 0.1% Tween 20, EDTA, < 0.14% dATP, dGTP, dCTP, dUTPs, < 0.01% upstream and downstream ZIKA primers, < 0.01% internal control forward and reverse primers, < 0.01% fluorescent-labeled ZIKA and internal control probes, < 0.01% oligonucleotide aptamer, < 0.01% Z05D DNA polymerase, < 0.01% AmpErase (uracil-N-glycosylase) enzyme (microbial), < 0.1% sodium azide | 17.5 mL |

Table 2 cobas® Zika Control Kit

Store at 2-8°C

(P/N 08129690190)

| Kit components | Reagent ingredients | Quantity per kit | Safety symbol and warning* |
|---|--|----------------------|--|
| Zika Positive Control (Zika (+) C) | < 0.001% Synthetic (armored) Zika RNA encapsulated in MS2 bacteriophage coat protein, Normal human plasma, Zika RNA not detectable by PCR methods. 0.1% ProClin® 300 preservative** | 16 mL (16 x 1 mL) |  <p>WARNING H317: May cause an allergic skin reaction. P261: Avoid breathing dust/fume/gas/mist/vapours/spray. P272: Contaminated work clothing should not be allowed out of the workplace. P280: Wear protective gloves. P333 + P313: If skin irritation or rash occurs: Get medical advice/attention. P362 + P364: Take off contaminated clothing and wash it before reuse. P501: Dispose of contents/ container to an approved waste disposal plant. 55965-84-9 reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H -isothiazol-3-one [EC no. 220-239-6] (3:1)</p> |



* Product safety labeling primarily follows EU GHS guidance

** Hazardous substance

Table 3 cobas® NHP Negative Control Kit

Store at 2-8°C

(P/N 07002220190)


| Kit components | Reagent ingredients | Quantity per kit | Safety symbol and warning* |
|--|--|----------------------|---|
| Normal Human Plasma Negative Control (NHP-NC) | Normal human plasma, Zika RNA not detectable by PCR methods. < 0.1% ProClin® 300 preservative** | 16 mL (16 x 1 mL) |   <p>WARNING H317: May cause an allergic skin reaction. P261: Avoid breathing dust/fume/gas/mist/vapours/spray. P272: Contaminated work clothing should not be allowed out of the workplace. P280: Wear protective gloves. P333 + P313: If skin irritation or rash occurs: Get medical advice/attention. P362 + P364: Take off contaminated clothing and wash it before reuse. P501: Dispose of contents/ container to an approved waste disposal plant. 55965-84-9 mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1)</p> |

* Product safety labeling primarily follows EU GHS guidance

** Hazardous substance

cobas omni reagents for sample preparation

Table 4 cobas omni reagents for sample preparation*

| Reagents | Reagent ingredients | Quantity per kit | Safety symbol and warning** |
|--|--|------------------|---|
| cobas omni MGP Reagent (MGP) Store at 2–8°C (P/N 06997546190) | Magnetic glass particles, Tris buffer, 0.1% methyl-4 hydroxybenzoate, < 0.1% sodium azide | 480 tests | Not applicable |
| cobas omni Specimen Diluent (SPEC DIL) Store at 2–8°C (P/N 06997511190) | Tris buffer, 0.1% methyl-4 hydroxybenzoate, < 0.1% sodium azide | 4 x 875 mL | Not applicable |
| cobas omni Lysis Reagent (LYS) Store at 2–8°C (P/N 06997538190) | 42.56% (w/w) guanidine thiocyanate***, 5% (w/v) polydocanol***, 2% (w/v) dithiothreitol***, dihydro sodium citrate | 4 x 875 mL |  <p>DANGER</p> <p>H302 + H332: Harmful if swallowed or if inhaled. H314: Causes severe skin burns and eye damage. H412: Harmful to aquatic life with long lasting effects. EUH032: Contact with acids liberates very toxic gas. P261: Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray. P273: Avoid release to the environment. P280: Wear protective gloves/protective clothing/eye protection/face protection. P303 + P361 + P353: IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water. P304 + P340 + P310: IF INHALED: Remove person to fresh air and keep comfortable for breathing. Immediately call a POISON CENTER/doctor. P305 + P351 + P338 + P310: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/doctor. 593-84-0 guanidinium thiocyanate 9002-92-0 Polidocanol 3483-12-3 (R*,R*)-1,4-dimercaptobutane-2,3-diol</p> |
| cobas omni Wash Reagent (WASH) Store at 15–30°C (P/N 06997503190) | Sodium citrate dihydrate, 0.1% methyl-4 hydroxybenzoate | 4.2 L | Not applicable |

* These reagents are not included in the cobas® Zika test kit. See listing of additional materials required (Table 7).

**Product safety labeling primarily follows EU GHS guidance.

*** Hazardous substance

Reagent storage and handling requirements

Opened reagents shall be stored and will be handled as specified in [Table 5](#) and [Table 6](#).

When reagents are not loaded on the **cobas**® 6800/8800 Systems, store them at the corresponding temperature specified in [Table 5](#).

Table 5 Reagent storage (when reagent is not on the system)

| Reagent | Storage temperature |
|---|---------------------|
| cobas ® Zika - 480 | 2-8°C |
| cobas ® Zika Control Kit | 2-8°C |
| cobas ® NHP Negative Control Kit | 2-8°C |
| cobas omni Lysis Reagent | 2-8°C |
| cobas omni MGP Reagent | 2-8°C |
| cobas omni Specimen Diluent | 2-8°C |
| cobas omni Wash Reagent | 15-30°C |

Reagents loaded onto the **cobas**® 6800/8800 Systems are stored at appropriate temperatures and their expiration is monitored by the system. The system allows reagents to be used only if all of the conditions shown in [Table 6](#) are met. The system automatically prevents use of expired reagents. [Table 6](#) allows the user to understand the reagent handling conditions enforced by the **cobas**® 6800/8800 Systems.

Table 6 Reagent expiry conditions enforced by the **cobas**® 6800/8800 Systems

| Reagent | Kit expiration date | Open-kit stability | Number of runs for which this kit can be used | On-board stability (cumulative time on board outside refrigerator) |
|---|---------------------|-----------------------------|---|--|
| cobas ® Zika - 480 | Date not passed | 30 days from first usage | Max 20 runs | Max 20 hours |
| cobas ® Zika Control Kit | Date not passed | Not applicable ^a | Not applicable | Max 10 hours |
| cobas ® NHP Negative Control Kit | Date not passed | Not applicable ^a | Not applicable | Max 10 hours |
| cobas omni Lysis Reagent | Date not passed | 30 days since loading* | Not applicable | Not applicable |
| cobas omni MGP Reagent | Date not passed | 30 days since loading* | Not applicable | Not applicable |
| cobas omni Specimen Diluent | Date not passed | 30 days since loading* | Not applicable | Not applicable |
| cobas omni Wash Reagent | Date not passed | 30 days since loading* | Not applicable | Not applicable |

^a Single use reagents

* Time is measured from the first time that reagent is loaded onto the **cobas**® 6800/8800 Systems.

Additional materials required

Table 7 Material and consumables for use on **cobas®** 6800/8800 Systems

| Material | P/N |
|--|-------------|
| cobas omni Processing Plate | 05534917001 |
| cobas omni Amplification Plate | 05534941001 |
| cobas omni Pipette Tips | 05534925001 |
| cobas omni Liquid Waste Container | 07094388001 |
| cobas omni Lysis Reagent | 06997538190 |
| cobas omni MGP Reagent | 06997546190 |
| cobas omni Specimen Diluent | 06997511190 |
| cobas omni Wash Reagent | 06997503190 |
| Solid Waste Bag | 07435967001 |
| Solid Waste Container | 07094361001 |

Instrumentation and software required

The **cobas®** 6800/8800 software and **cobas®** Zika analysis package shall be installed on the instrument(s). The Instrument Gateway (IG) server will be provided with the system. The **cobas®** **Synergy** software shall be installed, if applicable.

Table 8 Instrumentation

| Equipment | P/N |
|--|-----------------------------|
| cobas® 6800 System (Option Moveable) | 05524245001 and 06379672001 |
| cobas® 6800 System (Fix) | 05524245001 and 06379664001 |
| cobas® 8800 System | 05412722001 |
| Sample Supply Module | 06301037001 |
| Option for pipetting and pooling | P/N |
| cobas® Synergy Software Dongle | 07788339001 |
| Hamilton MICROLAB® STAR IVD | 04640535001 |

Refer to the **cobas®** 6800/8800 Systems Operator's Manual or to the **cobas®** **Synergy** software User Assistance for additional information about primary and secondary sample tubes accepted on the instruments.

Note: Contact your local Roche representative for a detailed order list for sample racks, racks for clotted tips and rack trays accepted on the instruments.

Precautions and handling requirements

Warnings and precautions

As with any test procedure, good laboratory practice is essential to the proper performance of this assay. Due to the high sensitivity of this test, care should be taken to keep reagents and amplification mixtures free of contamination.

- For *in vitro* diagnostic use only.
- All samples should be handled as if infectious, using good laboratory procedures as outlined in Biosafety in Microbiological and Biomedical Laboratories and in the CLSI Document M29-A4.^{31,32} Only personnel proficient in handling infectious materials and the use of **cobas**® Zika and **cobas**® 6800/8800 Systems should perform this procedure.
- All human-sourced materials should be considered potentially infectious and should be handled with universal precautions. If spillage occurs, immediately disinfect with a freshly prepared solution of 0.5% sodium hypochlorite in distilled or deionized water (dilute household bleach 1:10) or follow appropriate site procedures.
- **cobas**® Zika Control Kit and **cobas**® NHP Negative Control Kit contain plasma derived from human blood. Testing of normal human plasma by PCR methods showed no detectable Zika RNA. No known test method can offer complete assurance that products derived from human blood will not transmit infectious agents.
- Do not freeze whole blood.
- The use of sterile disposable pipettes and nuclease-free pipette tips is recommended. Use only supplied or specified required consumables to ensure optimal test performance.
- Closely follow procedures and guidelines provided to ensure that the test is performed correctly. Any deviation from the procedures and guidelines may affect optimal test performance.
- False positive results may occur if carryover of samples is not adequately controlled during sample handling and processing.

Reagent handling

- Handle all reagents, controls, and samples according to good laboratory practice in order to prevent carryover of samples or controls.
- Before use, visually inspect each reagent cassette, diluent, lysis reagent, and wash reagent to ensure that there are no signs of leakage. If there is any evidence of leakage, do not use that material for testing.
- **cobas omni** Lysis Reagent contains guanidine thiocyanate, a potentially hazardous chemical. Avoid contact of reagents with the skin, eyes, or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, burns can occur.
- **cobas**® Zika kits, **cobas omni** MGP Reagent, and **cobas omni** Specimen Diluent contain sodium azide as a preservative. Avoid contact of reagents with the skin, eyes, or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, burns can occur. If these reagents are spilled, dilute with water before wiping dry.
- Do not allow **cobas omni** Lysis Reagent, which contains guanidine thiocyanate, to contact sodium hypochlorite (bleach) solution. This mixture can produce a highly toxic gas.
- Safety Data Sheets (SDS) are available on request from your local Roche representative.
- Dispose of all materials that have come in contact with samples and reagents in accordance with country, state, and local regulations.

Good laboratory practice

- Do not pipette by mouth.
- Do not eat, drink, or smoke in designated work areas.
- Wear laboratory gloves, laboratory coats, and eye protection when handling samples and reagents. Gloves must be changed between handling samples and cobas® Zika kits and cobas omni reagents to prevent contamination. Avoid contaminating gloves when handling samples and controls. Change gloves if contaminated by sample, control, or reagents.
- Wash hands thoroughly after handling samples and kit reagents, and after removing the gloves.
- Thoroughly clean and disinfect all laboratory work surfaces with a freshly prepared solution of 0.5% sodium hypochlorite in distilled or deionized water (dilute household bleach 1:10). Follow by wiping the surface with 70% ethanol.
- If spills occur on the cobas® 6800/8800 instruments, follow the instructions in the cobas® 6800/8800 Systems Operator's Manual to properly clean and decontaminate the surface of instrument(s).

Sample collection, transport and storage


Note: Handle all samples and controls as if they are capable of transmitting infectious agents.

Store all donor samples at specified temperatures.


Sample stability is affected by elevated temperatures.

Living donor samples

- Plasma collected in EDTA and Becton-Dickinson EDTA Plasma Preparation Tubes (BD PPT™) may be used with cobas® Zika. Follow the sample collection tube/bag manufacturer instructions for handling and centrifugation.
- Blood collected in EDTA may be stored for up to 5 days with the following conditions:
 - Samples must be centrifuged within 72 hours of draw.
 - For storage above 8°C, samples may be stored for 72 hours at up to 25°C, and up to 30°C for 24 hours during the 72 hours.
- Other than noted above, samples are stored at 2-8°C. In addition, plasma separated from the cells may be stored for up to 30 days at $\leq -18^{\circ}\text{C}$ with two freeze/thaw cycles. Refer to [Figure 1](#).

Figure 1 Sample storage conditions for living donor samples collected in EDTA

- Blood collected in Becton-Dickinson EDTA Plasma Preparation Tubes (BD PPT™) may be stored for up to 7 days with the following conditions:
 - Samples must be centrifuged within 72 hours of draw.
 - For storage above 8°C, samples may be stored for 72 hours at up to 25°C, and up to 30°C for 24 hours during the 72 hours.
- Other than noted above, samples are stored at 2-8°C. Refer to [Figure 2](#).

Figure 2 Sample storage conditions for living donor samples collected in PPT

- If samples are to be shipped, they should be packaged and labeled in compliance with applicable country and/or international regulations covering the transport of samples and etiologic agents.

Instructions for use

Automated sample pipetting and pooling (optional)

cobas® Synergy Core can be used as an optional component of the cobas® 6800/8800 Systems for automated pipetting and pooling of aliquots of multiple primary samples into one pooled sample. Refer to the cobas® Synergy software User Assistance for more information.

Procedural notes


- Do not use cobas® Zika reagents, cobas® Zika Control Kit, cobas® NHP Negative Control Kit or cobas omni reagents after their expiry dates.
- Do not reuse consumables. They are for one-time use only.
- Refer to the cobas® 6800/8800 Systems Operator's Manual or to the cobas® Synergy software User Assistance as applicable for details on optional pooling procedures for proper maintenance of instruments.

Running cobas® Zika

The test procedure is described in detail in the cobas® 6800/8800 Systems Operator's Manual or refer to the cobas® Synergy software User Assistance as applicable for details on optional pooling procedures.

Figure 3 below summarizes the procedure.

Figure 3 cobas® Zika procedure



Results

The cobas® 6800/8800 Systems automatically detect Zika RNA simultaneously for the samples and controls.

Quality control and validity of results

- One negative control [(-) C] and one positive control [ZIKA (+) C] are processed with each batch.
- In the cobas® 6800/8800 software and/or report, check for flags and their associated results to ensure the batch validity.
- The batch is valid if no flags appear for both controls.

Invalidation of results is performed automatically by the cobas® 6800/8800 software based on negative and positive control failures.

Control flags

Table 9 Control flags for negative and positive controls

| Negative Control | Flag | Result | Interpretation |
|------------------|------|---------|---|
| (-) C | Q02 | Invalid | The entire batch is assigned invalid if the result for the (-) C is invalid. |
| Positive Control | Flag | Result | Interpretation |
| ZIKA (+) C | Q02 | Invalid | The entire batch is assigned invalid if the result for the ZIKA (+) C is invalid. |

If the batch is invalid, repeat testing of the entire batch including samples and controls.

Interpretation of results

For a valid batch, check each individual sample for flags in the cobas® 6800/8800 software and/or report. The result interpretation should be as follows:

- A valid batch may include both valid and invalid donor sample results dependent on flags obtained for the individual samples.
- Sample results are valid only if the respective positive control and the negative control of the corresponding batch are valid.

Two parameters are measured simultaneously for each sample: ZIKA and the internal control. Final sample results for the cobas® Zika test are reported by the software. In addition to the overall results, individual target result will be displayed in the cobas® 6800/8800 software and should be interpreted as follows:

Table 10 Target results for individual target result interpretation

| Target results | Interpretation |
|-------------------|--|
| ZIKA Non-Reactive | No target signal detected for ZIKA and IC signal detected. |
| ZIKA Reactive | Target signal detected for ZIKA and IC signal may be or may not be detected. |
| Invalid | Target and internal control signal not detected. |

Procedural limitations

- **cobas® Zika** has been evaluated only for use in combination with the **cobas® Zika Control Kit**, **cobas® NHP Negative Control Kit**, **cobas omni MGP Reagent**, **cobas omni Lysis Reagent**, **cobas omni Specimen Diluent**, and **cobas omni Wash Reagent** for use on the **cobas® 6800/8800 Systems**.
- Reliable results depend on proper sample collection, storage and handling procedures.
- Do not use heparinized plasma with this test because heparin has been shown to inhibit PCR.
- Detection of Zika RNA is dependent on the number of virus particles present in the sample and may be affected by sample collection, storage and handling, patient factors (i.e., age, presence of symptoms), and/or stage of infection.
- The **cobas® Zika** test is designed to detect Zika RNA in plasma samples, and Zika RNA may persist in certain organs and tissues, as well as other body fluids, longer than it is detectable in plasma.
- Though rare, mutations within the highly conserved regions of a viral genome covered by **cobas® Zika**, may affect primers and/or probe binding resulting in the failure to detect presence of virus.
- Due to inherent differences between technologies, it is recommended that, prior to switching from one technology to the next, users perform method correlation studies in their laboratory to qualify technology differences. Users should follow their own specific policies/procedures.

Non-clinical performance evaluation

Key performance characteristics - Living donor samples

Limit of Detection (LoD)

Roche Secondary Standard

The limit of detection (LoD) of cobas® Zika was determined using the Roche ZIKV Secondary Standard.

The Roche ZIKV Secondary Standard is a heat-inactivated virus culture supernatant (Strain MR766) and the titer is calculated based on the dilution factor from the stock. The stock titer was provided by the vendor (BNI, Bernhard Nocht Institute, Hamburg, Germany), and it was assigned using a serial dilution of ZIKV RNA transcript for which concentration was determined by photometric absorbance.

For the Roche ZIKV Secondary Standard, 3 independent dilution series of the viral standard were prepared with normal, virus-negative (Zika) human EDTA-plasma. Each dilution series was tested using two different lots of cobas® Zika kits with approximately 95 replicates per lot, for a total of approximately 190 replicates per concentration. For Zika virus, PROBIT analysis on the data combined across dilution series and reagent lots was used to estimate the LoD, along with the lower and upper limit of 95% confidence interval (Table 11). The reactivity rates observed in the LoD studies for Zika are summarized in Table 12.

Table 11 Results of PROBIT analysis on LoD data collected with viral standard in EDTA plasma

| Analyte | Measuring units | LoD | Lower 95% confidence limit | Upper 95% confidence limit |
|---------|-----------------|-----|----------------------------|----------------------------|
| Zika | cp/mL | 8.1 | 6.1 | 13.6 |

Table 12 Reactivity rates summary for Zika in EDTA plasma

| Zika RNA concentration (cp/mL) | Number reactive | Number of valid replicates | % Reactive | 95% Lower confidence bound (one-sided) |
|--------------------------------|-----------------|----------------------------|------------|--|
| 16.0 | 190 | 190 | 100.0% | 98.4% |
| 12.0 | 188 | 190 | 98.9% | 96.7% |
| 8.0 | 180 | 189 | 95.2% | 91.8% |
| 4.0 | 135 | 189 | 71.4% | 65.5% |
| 2.0 | 94 | 190 | 49.5% | 43.3% |

Analytical specificity

The analytical specificity of cobas® Zika was evaluated for cross-reactivity with 12 microorganisms at 10^5 - 10^6 particles, copies, or PFU/mL, which included 11 viral isolates and one bacterial strain (Table 13). The microorganisms were added to normal, virus-negative (Zika) human EDTA-plasma and tested with and without Zika virus added to a concentration of approximately 3 x LoD of cobas® Zika. The tested microorganisms do not cross-react or interfere with cobas® Zika.

Table 13 Microorganisms tested for analytical specificity

| Viruses | Bacteria |
|----------------------------------|---------------------------|
| Chikungunya Virus | <i>Treponema pallidum</i> |
| Dengue Virus Serotype 1 | - |
| Dengue Virus Serotype 2 | - |
| Dengue Virus Serotype 3 | - |
| Dengue Virus Serotype 4 | - |
| Japanese Encephalitis Virus | - |
| Murray Valley Encephalitis Virus | - |
| St. Louis Encephalitis Virus | - |
| Usutu Virus | - |
| West Nile Virus | - |
| Yellow Fever Virus | - |

Plasma samples from each of the disease states (Table 14) were tested with and without Zika virus added to a concentration of approximately 3 x LoD of cobas® Zika. These disease states did not cross-react or interfere with cobas® Zika.

Table 14 Disease state samples tested for analytical specificity

| Disease state |
|------------------------------|
| Human Immunodeficiency Virus |
| Hepatitis B Virus |
| Hepatitis C Virus |

Analytical specificity – interfering substances

Endogenous interference substances

Plasma samples with abnormally high levels of triglycerides (up to 33.2 g/L), hemoglobin (up to 2.9 g/L), unconjugated bilirubin (up to 0.28 g/L), albumin (up to 61.4 g/L), and human DNA (up to 0.002 g/L) were tested with and without Zika virus added to a concentration of 3 x LoD of cobas® Zika. Samples containing these endogenous substances did not interfere with the sensitivity or specificity of cobas® Zika.

Exogenous interference substances

Normal, virus-negative (Zika) human EDTA-plasma samples containing abnormally high concentrations of drugs (Table 15) were tested with and without Zika virus added to a concentration of 3 x LoD of cobas® Zika. These exogenous substances did not interfere with the sensitivity or specificity of cobas® Zika.

Table 15 Concentrations of the drugs added into EDTA-plasma

| Name of drug tested | Concentration |
|----------------------|---------------|
| Acetaminophen | 1337 µmol/L |
| Acetylsalicylic Acid | 3657 µmol /L |
| Ascorbic Acid | 346 µmol/L |
| Atorvastatin | 606 µg Eq/L |
| Fluoxetine | 11.3 µmol/L |
| Ibuprofen | 2450 µmol/L |
| Loratadine | 0.8 µmol/L |
| Nadolol | 3.9 µmol/L |
| Naproxen | 2192 µmol/L |
| Paroxetine | 3.1 µmol/L |
| Phenylephrine HCL | 496 µmol/L |
| Sertraline | 2.0 µmol/L |

Detection of Zika virus at LoD in clinical samples

Five Zika NAT-positive samples were singly diluted to ~13.6 copies/mL (~ 1 x LoD) into pooled negative EDTA plasma units. Twenty-one replicates were tested for each diluted sample.

All of the Zika samples diluted to near LoD were reactive for Zika and had reactive (valid) internal control (IC) results when tested using the cobas® Zika test (Table 16).

Table 16 Detection of Zika virus at LoD in clinical samples

| Specimens | Zika RNA concentration (cp/mL) | Number reactive | Number of valid replicates | % Reactive | 95% Lower confidence bound (one-sided) |
|-----------------------------|--------------------------------|-----------------|----------------------------|------------|--|
| 5 Zika NAT-positive samples | 13.6 | 105 | 105 | 100.0% | 97.2% |

Clinical performance evaluation

Reproducibility

The reproducibility of cobas® Zika for use on the cobas® 6800/8800 Systems was established by testing a twelve member panel composed of three negative plasma samples and three samples positive for Zika virus at three different concentrations (approximately 0.5 x, 1-2 x, and 3 x the LoD of cobas® Zika).

Operators at each of three sites performed five days of testing with each of three lots of cobas® Zika reagents and two valid panel runs (i.e., two batches, each batch composed of one panel and two independent controls) per day were completed to yield up to 270 tests per panel member virus type at each of the three concentrations.

All valid batches and test results were analyzed by calculating the percentage of reactive test results for each panel member (Table 17). This study demonstrated that cobas® Zika for use on the cobas® 6800/8800 Systems shows reproducible performance across the variables assessed (lot, site, day, batch, and within batch) for detecting Zika virus.

Table 17 Test results summarized by site, lot, day, and batch (positive panel members)

| Viral Concentration | Site ID | Site % Reactive Results | Lot ID | Lot % Reactive Results | Day ID | Day % Reactive Results | Batch ID | Batch % Reactive Results |
|---------------------|---------|----------------------------|--------|---------------------------|--------|---------------------------|----------|-----------------------------|
| ~0.5 x LoD | 1 | 82.2% (74/90) | 1 | 74.4% (67/90) | 1 | 74.1% (40/54) | 1 | 78.5% (106/135) |
| ~0.5 x LoD | 2 | 71.9% (64/89) | 2 | 78.7% (70/89) | 2 | 79.6% (43/54) | 2 | 73.7% (98/133) |
| ~0.5 x LoD | 3 | 74.2% (66/89) | 3 | 75.3% (67/89) | 3 | 79.6% (43/54) | - | - |
| ~0.5 x LoD | - | - | - | - | 4 | 73.1% (38/52) | - | - |
| ~0.5 x LoD | - | - | - | - | 5 | 74.1% (40/54) | - | - |
| 1-2 x LoD | 1 | 100.0% (89/89) | 1 | 100.0% (90/90) | 1 | 100.0% (54/54) | 1 | 100.0% (135/135) |
| 1-2 x LoD | 2 | 100.0% (90/90) | 2 | 100.0% (89/89) | 2 | 100.0% (53/53) | 2 | 100.0% (134/134) |
| 1-2 x LoD | 3 | 100.0% (90/90) | 3 | 100.0% (90/90) | 3 | 100.0% (54/54) | - | - |
| 1-2 x LoD | - | - | - | - | 4 | 100.0% (54/54) | - | - |
| 1-2 x LoD | - | - | - | - | 5 | 100.0% (54/54) | - | - |
| ~3 x LoD | 1 | 100.0% (90/90) | 1 | 100.0% (90/90) | 1 | 100.0% (54/54) | 1 | 100.0% (135/135) |
| ~3 x LoD | 2 | 100.0% (90/90) | 2 | 100.0% (90/90) | 2 | 100.0% (54/54) | 2 | 100.0% (135/135) |
| ~3 x LoD | 3 | 100.0% (90/90) | 3 | 100.0% (90/90) | 3 | 100.0% (54/54) | - | - |
| ~3 x LoD | - | - | - | - | 4 | 100.0% (54/54) | - | - |
| ~3 x LoD | - | - | - | - | 5 | 100.0% (54/54) | - | - |

Note: Within this table, separate summaries of the results from all replicates for each panel member virus concentration are presented for the variables site, lot, day and batch.

Clinical specificity

The clinical specificity of cobas® Zika was evaluated by testing individual samples from blood donations at five external laboratory sites in the Continental U.S. Four different cobas® Zika reagent lots were used in the study. Clinical specificity of cobas® Zika was calculated as the percentage (95% two-sided CI) of Zika donation status-negative donations that had cobas® Zika non-reactive results. There were 358,038 evaluable donations from individual testing.

Table 18 shows the calculation of clinical specificity of cobas® Zika for the 358,024 evaluable status-negative donations from individual testing. The clinical specificity of cobas® Zika from individual testing was 99.997% (358,015/358,024; 95% CI: 99.995% to 99.999%). An invalid rate of 0.09% due to internal control or other incidents was observed for individual sample results.

Table 18 Clinical specificity of cobas® Zika – individual testing (United States, not including the U.S. Territory of Puerto Rico)

| cobas® Zika Result | Zika Donation Status* | | Total |
|--|-----------------------|---------------------------------------|---------|
| | Positive | Negative | |
| Reactive | 14 | 9 | 23 |
| Non-Reactive | 0 | 358,015 | 358,015 |
| Total | 14 | 358,024 | 358,038 |
| Clinical Specificity (95% CI**) | - | 99.997% (99.995%, 99.999%) | - |

* Donation Status was assigned based on the testing reactivity pattern observed on the index donation (initial and additional index testing) and/or based on follow-up study results.

** Clopper-Pearson Exact method

Evaluation of the sensitivity of cobas® Zika

The evaluation of the sensitivity of cobas® Zika was done using 25 confirmed Zika-positive clinical samples at an internal testing site. The cobas® Zika test detected 100% (95% CI: 86.2%-100%).

Evaluation of the yield and PPV of cobas® Zika in a Zika outbreak

Under IND, individual donation testing in the Continental U.S. began during the Zika outbreak in 2016 and identified 14 (0.004%) initially reactive and confirmed samples from 358,038 donations tested. In that same timeframe, individual testing under IND in the U.S. territory of Puerto Rico identified 275 (0.74%) initially reactive and confirmed samples from 37,041 evaluable donations tested.

The Positive Predictive Value (PPV) of cobas® Zika was demonstrated by confirmation of reactive samples with an alternate NAT and/or presence of anti-Zika IgM and/or cobas® Zika reactivity through enrollment in a follow up study. In the Continental U.S., a low prevalence area during the Zika outbreak, among 23 initially reactive blood donor samples found, 14 were confirmed to be positive, yielding a PPV of 60.9% (95% CI: 38.5%-80.3%). During the same period in the U.S. territory of Puerto Rico, an area of high prevalence, among 286 initially reactive blood donations, 275 were confirmed to be positive, yielding a PPV of 96.2% (95% CI: 93.2%-98.1%).

Evaluation of pool reactivity of cobas® Zika

Reactivity in simulated pools of 6 was calculated from the 14 and 275 confirmed positive samples in the Continental U.S. and Puerto Rico, respectively. Six out of the 14 (42.9%, 95% CI: 17.7%-71.1%) confirmed positive samples from the Continental U.S. were reactive with cobas® Zika in simulated pools of 6. Two hundred and fourteen out of 275 (77.8%, 95% CI: 72.4%-82.6%) confirmed positive samples from Puerto Rico were reactive with cobas® Zika in simulated pools of 6.

Additional information





























Key test features

| | |
|-----------------------------------|--|
| Sample type | Plasma |
| Amount of sample required | 1000 µL |
| Amount of sample processed | 850 µL |
| Test duration | Results are available within less than 3.5 hours after loading the sample on the system. |

Symbols

The following symbols are used in labeling for Roche PCR diagnostic products.

Table 19 Symbols used in labeling for Roche PCR diagnostics products

| | | | |
|---|---|---|---|
|  Age/DOB | Age or Date of Birth |  | Date of manufacture |
|  | Ancillary Software |  | Distributed by |
|  | Assigned Range (copies/mL) |  | Do not re-use |
|  | Assigned Range (IU/mL) |  | Female |
|  | Authorized representative in the European Community |  | For IVD performance evaluation only |
|  | Barcode Data Sheet |  | Global Trade Item Number |
|  | Batch code |  | <i>In vitro</i> diagnostic medical device |
|  | Biological risks |  | Lower Limit of Assigned Range |
|  | Catalogue number |  | Male |
|  | Collect date |  | Manufacturer |
|  | Consult instructions for use |  | Negative control |
|  | Contains sufficient for <n> tests |  | Non sterile |
|  | Contents of kit |  | Patient number |
|  | Control |  | Patient Name |



Peel here




This way up



Positive control




Unique Device Identification



QS copies per PCR reaction, use the QS copies per PCR reaction in calculation of the results.



Ultrasensitive Procedure



QS IU per PCR reaction, use the QS International Units (IU) per PCR reaction in calculation of the results.



Upper Limit of Assigned Range



Urine Fill Line



Serial number

Rx Only

US Only: Federal law restricts this device to sale by or on the order of a physician.



Site



Use-by date



Standard Procedure



Device for near-patient testing



Sterilized using ethylene oxide



Device Not for Near Patient Testing



Store in the dark



Device for self-testing



Temperature limit



Device not for self-testing



Test Definition File



CE marking of conformity; this device is in conformity with the applicable requirements for CE marking of an *in vitro* diagnostic medical device

US Customer Technical Support 1-800-526-1247

Manufacturer and distributors

Table 20 Manufacturer and distributors



Manufactured in the United States

Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim, Germany
www.roche.com
U.S. License No. 1636

Made in USA

Distributed by

Roche Diagnostics
9115 Hague Road
Indianapolis, IN 46250-0457 USA
(For Technical Assistance call the
Roche Response Center
Toll-free: 1-800-526-1247)

Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim, Germany

Trademarks and patents

This product is covered by one or more of US Patent Nos. 8962293, 9102924, 8609340, 9234250, 8097717, 8192958, 10059993, 10358675, and foreign equivalent patents of each.

COBAS, COBAS OMNI, and AMPERASE are trademarks of Roche.

The trademark “Armored RNA®” is owned by Asuragen, Inc. and Cenetron Diagnostics, Ltd.

ProClin® is a registered trademark of Rohm and Haas Company.

MICROLAB® is a registered trademark of the Hamilton Company.

BD PPT™ is a trademark of Becton Dickinson & Company.

All other product names and trademarks are the property of their respective owners.

Carryover prevention technology in the AmpErase enzyme is covered by U.S. Patent 7,687,247 owned by Life Technologies and licensed to Roche Molecular Systems, Inc.

See <http://www.roche-diagnostics.us/patents>

Copyright

©2021 Roche Molecular Systems, Inc.

References

1. Marano G, Pupella S, Vaglio S, Liunbruno GM, Grazzini G. Zika virus and the never-ending story of emerging pathogens and transfusion medicine. *Blood Transfus.* 2016;14(2):95-100. PMID: 26674815.
2. Stramer SL. Current perspectives on transfusion-transmitted infectious disease: emerging and re-emerging infections. *ISBT Science Series.* 2014;9:30-6. PMID: 25210533.
3. Kuno G, Chang GJ, Tsuchiya KR, Karabatsos N, Cropp CB. Phylogeny of the genus *Flavivirus*. *J Virol.* 1998;72(1):73-83. PMID: 9420202.
4. Baronti C, Piorkowski G, Charrel RN, Boubis L, LeParc-Goffart I, de Labbellerie X. Complete coding sequence of Zika virus from a French polynesia outbreak in 2013. *Genome Announc.* 2014;2(3):e00500-00514. PMID: 24903869.
5. Ioos S, Mallet HP, Leparc Goffart I, Gauthier V, Cardoso T, Herida M. Current Zika virus epidemiology and recent epidemics. *Med Mal Infect.* 2014;44(7):302-7. PMID: 25001879.
6. Hennessey M, Fischer M, Staples E. Zika virus spreads to new areas—regions of the Americas, May 2015-January 2016. *MMWR Morb Mortal Wkly Rep.* 29 January 2016;65(3):55-8. PMID: 26820163.
7. Hayes EB. Zika virus outside Africa. *Emerg Infect Dis.* 2009;15(9):1347-50. PMID: 19788800.
8. Lanciotti RS, Kosoy OL, Laven JJ, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. *Emerg Infect Dis.* 2008;14(8):1232-9. PMID: 18680646.
9. Duffy MR, Chen TH, Hancock WT, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. *N Engl J Med.* 2009;360(24):2536-43. PMID: 19516034.
10. Grard G, Caron M, Mombo IM, et al. Zika virus in Gabon (Central Africa)--2007: a new threat from *Aedes albopictus*? *PLoS Negl Trop Dis.* 2014;8(2):1-8. PMID: 24516683.
11. Musso D, Nhan T, Robin E, et al. Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014. *Euro Surveill.* 2014;19(14):6-8. PMID: 24739982.
12. Boadle A. Brazil reports Zika infection from blood transfusions. *Reuters.com.* February 4, 2016. www.reuters.com/article/us-health-zika-brazil-blood-idUSKCN0VD22N.
13. U.S. Centers for Disease Control and Prevention. Zika virus home: transmission. <http://www.cdc.gov/zika/transmission/index.html> (last updated January 3, 2017; accessed February 17, 2016).
14. U.S. FDA. Guidance for industry: recommendations for donor screening, deferral, and product management to reduce the risk of transfusion-transmission of Zika virus. February 2016. <http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM486360.pdf>.
15. Oehler E, Watrin L, Larre P, Leparc-Goffart I, et al. Zika virus infection complicated by Guillain-Barre syndrome--case report, French Polynesia, December 2013. *Euro Surveill* 2014;19(9):1-3. PMID: 24626205.
16. Musso D, Roche C, Robin E, Teissier A, et al. Potential sexual transmission of Zika virus. *Emerg Infect Dis* 2015;21:359-61. PMID 25625872.

17. Oster AM, Brooks JT, Stryker JE, Kachur RE, et al. Interim guidelines for prevention of sexual transmission of Zika virus-United States 2016. *MMWR Morb Mortal Wkly Rep* 12 February 2016;65(5):120-1. PMID 26866485.
18. Foy BD, Kobylinski KC, Chilson Foy JL, Blitvich BJ, et al. Probable non-vector-borne transmission of Zika virus, Colorado, USA. *Emerg Infect Dis* 2011;17(5):880-2. doi:10.3201/eid1750.101939. PMID 21529401.
19. Dallas County Health & Human Services. <http://www.dallascounty.org/department/hhs/press/documents/PR2-2-16DCHHSReportsFirstCaseofZikaVirusThroughSexualTransmission.pdf>.
20. McNeil DG, Tavernise S. Zika infection transmitted by sex reported in Texas. *NY Times* February 3, 2016. http://www.nytimes.com/2016/02/03/health/Zika-sex-transmission-texas.html?_r=0.
21. Schuler-Faccini L, Ribeiro EM, Feitosa IM, et al. Possible association between Zika virus infection and microcephaly - Brazil, 2015. *MMWR Morb Mortal Wkly Rep*. 2016;65(3):59-62. PMID: 26820244.
22. Oliveira Melo AS, Malinger G, Ximenes R, Szejnfeld PO, Alves SS, Bispo de Filippis AM. Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of the iceberg? *Ultrasound Obstet Gynecol*. 2016;47:6-7. PMID 26731034.
23. Besnard M, Lastere S, Teissier A, Cao-Lormeau V, Musso D. Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. *Euro Surveill* 2014;19(13):1-4. PMID: 24721538.
24. Mlakar J, Korva M, Tul N, et al. Zika Virus Associated with Microcephaly. *N Engl J Med*. 2016;374(10):951-8. PMID: 26862926.
25. Balm MN, Lee CK, Lee HK, Chiu L, Koay ES, Tang JW. A diagnostic polymerase chain reaction assay for Zika virus. *J Med Virol*. 2012;84(9):1501-1505. PMID: 22825831.
26. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. *Gene*. 1990; 93:125-8.
27. Savva R, McAuley-Hecht K, Brown T, Pearl L. The structural basis of specific base-excision repair by uracil-DNA glycosylase. *Nature*. 1995; 373:487-93.
28. Mol CD, Arvai AS, Slupphaug G, et al. Crystal structure and mutational analysis of human uracil-DNA glycosylase: structural basis for specificity and catalysis. *Cell*. 1995;80:869-78.
29. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. *Biotechnology (NY)*. 1992;10:413-417.
30. Heid CA, Stevens J, Livak JK, Williams PM. Real time quantitative PCR. *Genome Res*. 1996;6:986-994.
31. Center for Disease Control and Prevention. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institutes of Health HHS Publication No. (CDC) 21-1112, revised December 2009.
32. Clinical and Laboratory Standards Institute (CLSI). Protection of laboratory workers from occupationally acquired infections. Approved Guideline-Fourth Edition. CLSI Document M29-A4:Wayne, PA;CLSI, 2014.

Document revision

| Document Revision Information | |
|--------------------------------------|--|
| Doc Rev. 5.0 02/2021 | Updated hazard warnings. Updated the harmonized symbol page. Updated distributors addresses. Added Made in statement. Updated trademarks and patents section. Updated the IFU formatting for Section 508 compliance. Please contact your local Roche Representative if you have any questions. |